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mbrisentan Therapy for
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nd Giessen, Germany
OBJECTIVES The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan,
an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial
hypertension (PAH).
BACKGROUND Pulmonary arterial hypertension is a life-threatening and progressive disease with limited
treatment options. Endothelin is a vasoconstrictor and smooth muscle cell mitogen that plays
a critical role in the pathogenesis and progression of PAH.
METHODS In this double-blind, dose-ranging study, 64 patients with idiopathic PAH or PAH
associated with collagen vascular disease, anorexigen use, or human immunodeficiency virus
infection were randomized to receive 1, 2.5, 5, or 10 mg of ambrisentan once daily for 12
weeks followed by 12 weeks of open-label ambrisentan. The primary end point was an
improvement from baseline in 6-min walk distance (6MWD); secondary end points included
Borg dyspnea index, World Health Organization (WHO) functional class, a subject global
assessment, and cardiopulmonary hemodynamics.
RESULTS At 12 weeks, ambrisentan increased 6MWD (36.1 m, p  0.0001) with similar and
statistically significant increases for each dose group (range, 33.9 to 38.1 m). Improve-
ments were also observed in Borg dyspnea index, WHO functional class, subject global
assessment, mean pulmonary arterial pressure (5.2 mm Hg, p  0.0001), and cardiac index
(0.33 l/min/m2, p 0.0008). Adverse events were mild and unrelated to dose, including the
incidence of elevated serum aminotransferase concentrations 3 times the upper limit of
normal (3.1%).
CONCLUSIONS Ambrisentan appears to improve exercise capacity, symptoms, and hemodynamics in patients
with PAH. The incidence and severity of liver enzyme abnormalities appear to be
low. (J Am Coll Cardiol 2005;46:529–35) © 2005 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.050Foundation
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sulmonary arterial hypertension (PAH) is defined as a
roup of diseases characterized by a progressive increase in
ulmonary vascular resistance leading to right ventricular
ailure and premature death (1). It includes idiopathic PAH
IPAH) and PAH associated with various conditions such
s collagen vascular disease, congenital systemic-to-
ulmonary shunts, portal hypertension, anorexigen use, and
uman immunodeficiency virus infection (1,2).
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005, accepted April 14, 2005.Endothelin (ET), a peptide produced primarily by vas-
ular endothelial cells, has been characterized as a powerful
asoconstrictor and mitogen for smooth muscle (3,4). Ac-
ivation of the ET system has been shown in both plasma
5) and lung tissue (6) of PAH patients, as well as in animal
odels of PAH (7), supporting a prominent role of ET in
he pathogenesis of this condition (8).
Endothelin binds to two types of receptors, ETA and
TB. The ETA receptors are found in smooth muscle cells,
hereas ETB receptors are localized on both endothelial
ells and smooth muscle cells (9). Activation of ETA and
TB receptors on smooth muscle cells mediates the vaso-
onstrictive and mitogenic effects of ET (8). Stimulation of
ndothelial ETB receptors promotes ET clearance and
ctivation of nitric oxide and prostacyclin release, which
nduces vasodilation and antiproliferative effects (8). Selec-
ive ETA receptor antagonism may be more beneficial than
ntagonism of both ETA and ETB receptors by inhibiting
asoconstrictive and mitogenic effects of ETA receptor
timulation while preserving the natural vasodilator and
learance responses induced by ET through ETB receptors.
r
t
m
s
u
n
o
i
s
c
a
M
S
a
a
s
P
v
c
w
p
n
p
t
e
l
i
p
c
b
t
w
t
b
m
s
S
d
E
r
o
2
b
1
t
(
a
p
t
p
a
b
w
a
A
t
O
c
b
T
a
z
a
o
t
t
d
P
s
u
q
d
z
C
a
c
w
a
t
w
F
r
t
530 Galié et al. JACC Vol. 46, No. 3, 2005
Ambrisentan and PAH August 2, 2005:529–35To date, bosentan, an orally active, dual ETA and ETB
eceptor antagonist, is the only approved endothelin recep-
or antagonist (ERA) for the treatment of PAH (10). The
ajor limitation of bosentan treatment is the elevation of
erum aminotransferase concentrations to 3 times the
pper limit of normal in 12% of cases.
Ambrisentan is a potent ETA-selective receptor antago-
ist with a bioavailability and half-life (9 to 15 h) that allows
nce-daily dosing (11). We present the results of a random-
zed dose-ranging study that examined the efficacy and
afety of ambrisentan in patients with PAH. This study was
omposed of a 12-week, double-blind, fixed-dose period
nd a 12-week, open-label extension period.
ETHODS
tudy population. Male and female patients 18 years of
ge or older with symptomatic PAH despite treatment with
nticoagulants, vasodilators, diuretics, cardiac glycosides, or
upplemental oxygen for at least 4 weeks were enrolled. The
AH was either idiopathic or was associated with collagen
ascular disease, anorexigen use, or human immunodefi-
iency virus infection. Inclusion criteria included a 6-min
alk distance (6MWD) between 150 and 450 m, mean
ulmonary arterial pressure (mPAP) 25 mm Hg, pulmo-
ary vascular resistance (PVR) 240 dynes · s/cm5, and
ulmonary capillary wedge pressure (PCWP) or left ven-
ricular end diastolic pressure 15 mm Hg. Patients were
xcluded from the study if they had congenital heart defects,
eft-sided myocardial disease, valvular heart disease, signif-
cant parenchymal lung disease, chronic thromboembolic
ulmonary hypertension, or portal hypertension; had re-
eived chronic prostanoid or ERA therapy within 4 weeks
efore study entry; or had serum aminotransferase concen-
rations 1.5 times the upper limit of normal. The study
as conducted according to the ethical principles stated in
he Declaration of Helsinki and in adherence with applica-
le guidelines for good clinical practice. Local ethics com-
ittees approved the protocol, and written informed con-
ent was obtained from all patients.
tudy design. The study was a randomized, double-blind,
ose-controlled trial conducted in 20 centers in the U.S.,
urope, and Australia. Patients were randomly assigned to
eceive a blinded dose of 1, 2.5, 5, or 10 mg of ambrisentan
Abbreviations and Acronyms
6MWD 6-min walk distance
ERA  endothelin receptor antagonist
ET  endothelin
IPAH  idiopathic pulmonary arterial hypertension
mPAP  mean pulmonary arterial pressure
PAH  pulmonary arterial hypertension
PCWP  pulmonary capillary wedge pressure
PVR  pulmonary vascular resistance
WHO  World Health Organizationrally once daily. Patients randomized to the 1- and
a
o.5-mg-dose groups received their assigned dose of am-
risentan for 12 weeks. Patients randomized to the 5- or
0-mg-dose groups initially received 2.5 mg, and doses were
itrated upward over several weeks to the randomized dose
Fig. 1).
Primary and secondary efficacy assessments were collected
fter 12 weeks of double-blind treatment. After 12 weeks,
atients were unblinded and had the option to continue
reatment for an additional 12 weeks (open-label extension
eriod). During this time, the dose of ambrisentan could be
djusted based on the investigator’s assessment of clinical
enefit and adverse events. More than half of the patients
ho participated in the open-label extension period received
different dose of study drug than their randomized dose.
ll patients who completed the 24-week study were eligible
o enter a long-term open-label study.
utcome measures. The primary efficacy end point was a
hange in exercise capacity, as measured by the change from
aseline in 6MWD, evaluated after 12 weeks of therapy.
he secondary end points included a change from baseline
t week 12 in Borg dyspnea index, World Health Organi-
ation (WHO) functional class, quality of life as assessed by
subject global assessment, and time to clinical worsening
f PAH. Clinical worsening of PAH was defined by the
ime to first occurrence of death, all-cause hospitalizations,
he addition of a new diuretic or a doubling of the dose of
iuretic, or study withdrawal because of a need for other
AH therapeutic agents (defined as prostanoids, ERAs, or
ildenafil). The subject global assessment was determined
sing a visual analog scale (12). Patients were asked the
uestion, “How are you feeling today?” and were asked to
raw a vertical mark on a 100-mm horizontal line in which
ero represented very poor and 100 represented excellent.
ardiopulmonary hemodynamics were collected at baseline
nd week 12 in a subset of patients enrolled at pre-specified
enters. Pharmacokinetics were evaluated at baseline and at
eek 12 in a subset of patients. Vital signs, adverse events,
nd clinical laboratory measurements were evaluated every
wo weeks for safety. The protocol stipulated that patients
ould receive a reduced dose or discontinued study drug if
igure 1. The study design. Subjects randomized to the 5-mg dose group
eceived 2.5 mg for 2 weeks and 5 mg for 10 weeks. Subjects randomized
o the 10-mg dose group received 2.5 mg for 2 weeks, 5 mg for 2 weeks,
nd 10 mg for 8 weeks. Dose adjustments were allowed during the optional
pen-label extension period (weeks 13 to 24).
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August 2, 2005:529–35 Ambrisentan and PAHerum aminotransferase concentrations developed that were
3 or 5 times the upper limit of normal, respectively.
tatistical analysis. All randomized patients were followed
p to the end of the study and included in the analyses of
fficacy and safety (intent-to-treat analysis). The null hy-
othesis of the study was no change from baseline to week
2 in 6MWD for a single-dose group, and a one-sample t
est was used to test the null hypothesis for each dose. A
ample size of 15 patients for a single-dose group was
stimated to provide 80% power to detect a 50-m change
rom baseline, according to a one-sample t test with a type
error of 0.05 (two-sided) and a standard deviation of 69.5
. Linear regression modeling was used to examine the null
ypothesis of no linear relationship between the four doses of
mbrisentan and the change from baseline in the distance
alked during the 6-min walk test for each dose measured at
eek 12. A sample size of 60 patients was estimated to provide
0% power to detect a correlation (r) of 0.35 (an r2 of 12%),
ssuming a type I error of 0.05 (two-sided).
For the primary end point, the last 6MWD recorded was
sed for all missing data at week 12 (last observation carried
orward). For the secondary end points, no imputations for
issing data were performed unless stated otherwise. The
ime to clinical worsening of PAH was displayed as a
aplan-Meier curve for each dose group. Differences be-
ween curves were tested for significance by the log-rank test
nd by the Cox proportional hazards model (linear and
ogarithmic). Dose adjustments were allowed during the open-
abel extension period (weeks 13 to 24); therefore, the results
rom all dose groups during this period were combined to
xamine efficacy and safety. Data are reported as mean or mean
standard error of the mean if not otherwise stated.
ESULTS
atients. A total of 64 patients were randomized to one of
our dose groups (1, 2.5, 5, and 10 mg ambrisentan).
able 1. Demographics and Clinical Characteristics at Baseline
Ambrisentan Dose*
1 mg
(n  16)
emale, n (%) 14 (87)
ge, yrs 53  17
thnicity, n (%)
Caucasian 11 (69)
Non-Caucasian 4 (25)
Information unavailable 1 (6)
tiology of PAH, n (%)
Idiopathic PAH 9 (56)
PAH associated with collagen vascular disease 7 (44)
PAH associated with anorexigen use 0 (0)
PAH associated with HIV infection 0 (0)
HO functional class, n (%)
II 6 (37)
III 10 (63)
-min walk distance, m 355  77
Differences between dose groups were non-significant by Fisher’s exact test and two-s
roups (p  0.05) and the 5- and 10-mg groups (p  0.01). Values shown are mean  S
HIV  human immunodeficiency virus; PAH  pulmonary arterial hypertension; WHaseline characteristics of the four dose groups were gener-
lly well matched (Table 1), including several key hemody-
amic variables (Table 2). However, baseline 6MWDs
ndicate that the patients who received the 10-mg dose may
ave represented a somewhat sicker population.
Three patients discontinued the study because of adverse
vents during the 12-week treatment period: two patients
ecause of sudden death (1- and 10-mg-dose groups) and
ne patient because of elevated serum aminotransferase
oncentrations (5-mg-dose group). Three patients in the
.5-mg-dose group also discontinued: one patient because
f an inclusion criteria violation (pulmonary capillary wedge
ressure 15 mm Hg), one patient voluntarily withdrew,
nd one patient was lost to follow-up. All six patients had
heir last 6MWD carried forward to the 12-week assess-
ent. Two patients (1- and 5-mg-dose groups) who com-
leted the 12-week treatment period did not have the
ption to participate in the 12-week open-label extension
eriod. One patient in the 5-mg-dose group voluntarily
ithdrew from the open-label extension period, and one
atient in the 10-mg-dose group voluntarily discontinued
rom the open-label extension period because of lack of
mprovement.
xercise capacity. The 6MWD improved for all dose
roups combined after 12 weeks of treatment, with a mean
ncrease from baseline of 36.1 m (p  0.0001). A similar
mprovement was observed in all dose groups: 33.9 (p 
.0029), 37.1 (p  0.0004), 38.1 (p  0.0112), and
35.1 (p  0.0080) m for the 1-, 2.5-, 5-, and 10-mg-dose
roups, respectively, and no dose-response relationship was
bserved (Fig. 2A). Subgroup analyses (Figs. 2B and 2C)
ndicate that the 6MWD increased in patients with IPAH
39.9 m, p 0.0001) as well as in patients with PAH due
o other etiologies (30.2, p  0.0026) and for patients in
HO functional class II (37.7 m, p  0.003) as well as
n those in WHO functional class III (35.2, p  0.001).
2.5 mg
(n  19)
5 mg
(n  16)
10 mg
(n  13)
All Doses
(n  64)
18 (95) 12 (75) 10 (77) 54 (84)
52  17 48  16 53  12 51  16
14 (74) 10 (63) 10 (77) 45 (70)
5 (26) 5 (31) 3 (23) 17 (27)
0 (0) 1 (6) 0 (0) 2 (3)
11 (60) 12 (75) 7 (54) 39 (61)
6 (30) 2 (13) 4 (31) 19 (30)
1 (5) 1 (6) 2 (15) 4 (6)
1 (5) 1 (6) 0 (0) 2 (3)
6 (32) 8 (50) 3 (23) 23 (36)
13 (68) 8 (50) 10 (77) 41 (64)
340  59 378  75 289  91 343  79
t test, with the exception of baseline 6-min walk distance between the 1- and 10-mgample
D unless otherwise noted.
O  World Health Organization.
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Ambrisentan and PAH August 2, 2005:529–35mprovements in exercise capacity were maintained and
ontinued to increase up to 24 weeks: 50.2 (p  0.0001),
50.9 (p  0.0001), and 54.2 m (p  0.0001) at 16, 20,
nd 24 weeks, respectively (Fig. 3). At week 24, there was a
arger improvement in 6MWD for IPAH patients com-
ared with patients with other etiologies (64.3 and 38.5
, respectively; p  0.05, two-sample t test), whereas
imilar improvement continued to be observed for WHO
unctional class II and class III patients (58.3 and 51.9
, respectively).
At week 12, there was a mean improvement from baseline
as indicated by a decrease) in the Borg dyspnea index score
f 0.6  0.5, 0.9  0.4, 1.0  0.6, and 1.0  0.6
or the 1-, 2.5-, 5-, and 10-mg-dose groups, respectively.
he Borg dyspnea index score at baseline for all dose groups
ombined was 4.0  0.3, which improved by 0.9  0.3 (p
0.0015) at week 12 and was maintained through week 24
1.3  0.3, p  0.0001).
HO functional class. Improvements in WHO func-
ional class were observed for all dose groups, yet no
ose-response relationship was observed. At baseline, 64%
f the patients were WHO class III with the remainder
eing WHO class II. By week 12, 38% of patients were
HO class III, 50% were WHO class II, and 12% were
HO class I (Fig. 4). Eighteen patients (36.2%, 95%
onfidence interval 25.7% to 46.7%) improved one or more
HO functional classes, whereas only two patients (3.4%,
5% confidence interval9.4% to 16.2%) worsened at week
2. The improvements in WHO functional class continued
o be maintained through week 24.
linical worsening. By week 12, clinical worsening of
AH was observed in 13 of 64 patients (20.3%). In 6
46.2%) of the 13 patients in whom clinical worsening of
AH developed, as defined in the protocol, it was caused by
n increase of the dose of diuretic. There was no correlation
etween the dose of ambrisentan and the incidence of
able 2. Cardiopulmonary Hemodynamics
Ambrisentan Dose 1 mg 2.5 m
umber of patients
Baseline§ 10 9
Change from baseline 9 8
ean cardiac index (l/min/m2)
Baseline 2.5  0.5 2.4 
Change from baseline 0.10  0.31 0.41 
ean PAP (mm Hg)
Baseline 50  18 49 
Change from baseline 4.3  4.0* 4.3 
ean PVR (dyn · sec/cm5)
Baseline 839  483 804 
Change from baseline 178  98* 173 
ean RAP (mm Hg)
Baseline 7.3  4.0 9.1 
Change from baseline 0.89  3.44 1.13 
p  0.05. †p  0.056. ‡n  8 for pulmonary vascular resistance in the 1-mg-dos
ulmonary capillary wedge pressure reading. Values shown are mean  SD.
PAP  pulmonary artery pressure; PVR  pulmonary vascular resistance; RAPncreased diuretics. Neither log-rank analysis nor Cox pro- vortional hazards models indicated any significant difference
n times to clinical worsening of PAH among dose groups.
uring the open-label extension period, there were eight
atients in whom clinical worsening developed; all but three
ases were attributable to an increased dose of diuretics.
ubject global assessment. At baseline, the mean subject
lobal assessment score for all dose groups combined was
6.4  2.6 mm, which improved by 11.3  2.4 mm (p 
.0001) at week 12. When missing data at week 12 were
eplaced with a subject global assessment score of 0 mm
maximum penalty), the subject global assessment improved
rom baseline by 23.2% (p  0.0232, one-sample t test) for
ll dose groups combined. No differences among dose
roups were observed. In the open-label extension period,
he improvement was maintained up to 24 weeks (12.1 
.7 mm, p  0.0001).
emodynamics. Cardiopulmonary hemodynamics at
aseline and week 12 for a subset of patients are reported in
able 2. Mean pulmonary artery pressure decreased in all
ose groups combined as well as for the 1-, 5-, and
0-mg-dose groups. Cardiac index increased in all dose
roups combined, as well as for the 2.5- and 5-mg-dose
roups. Pulmonary vascular resistance decreased in all
ose groups combined, as well as for the 1-, 2.5-, and
-mg-dose groups. A non-significant trend toward reduc-
ion in right atrial pressure was observed, with the exception
f the 1-mg-dose group.
harmacokinetics. Single-dose and steady-state plasma
oncentration time profiles were biphasic and steady-state
harmacokinetics were predictable based on data from
ingle doses. The onset of absorption was rapid, with a
aximum plasma concentration at steady-state that ranged
rom 111 to 1,223 ng/ml occurring 1.7 to 3.3 h after dosing
nd a mean elimination half-life at steady-state that ranged
rom 9 to 15 h.
afety and tolerability. The most frequently reported ad-
5 mg 10 mg All Doses
10 5 34
9 3 29
2.3  0.6 2.5  0.5 2.4  0.5
0.47  0.62* 0.37  0.16† 0.33  0.47*
47  10 52  11 49  13
4.3  4.8* 13.3  5.1* 5.2  6.2*
881  339 828  416 840  407
277  261* 345  226 226  202*
5.2  3.5 8.2  2.9 7.3  4.5
0.44  4.77 2.67  5.51 0.45  4.75
p, and n  28 for all doses combined, because one patient did not have a baseline
t atrial pressure.g
0.6
0.48*
13
8.4
457
199*
6.1
6.08
e grouerse events during the 12-week blinded treatment period
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August 2, 2005:529–35 Ambrisentan and PAHere peripheral edema (25.0%), nasal congestion (18.8%),
pper respiratory tract infection (18.8%), headache (15.6%),
ushing (12.5%), and nausea (12.5%). No clinically mean-
ngful differences among the four doses were observed for
he total number of adverse events, the incidence of adverse
vents per patient, adverse event severity, or relationship to
tudy drug. Seven patients experienced serious adverse
vents during the 12-week blinded treatment period, in-
luding two sudden deaths (1- and 10-mg-dose groups). In
oth cases, the investigator judged the death not related to
he study drug.
During the 24-week study (Table 3), in one patient
igure 2. (A) Mean change from baseline in 6-min walk distance
6MWD) for all patients at week 12 for the 1-, 2.5-, 5-, and 10-mg-dose
roups and for all dose groups combined. (B) Mean change from baseline
n 6MWD for idiopathic pulmonary arterial hypertension patients at week
2 for the 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups
ombined. (C) Mean change from baseline in 6MWD for patients with
ulmonary arterial hypertension associated with collagen vascular disease,
norexigen use, or human immunodeficiency virus infection at week 12 for
he 1-, 2.5-, 5-, and 10-mg-dose groups and for all dose groups combined.
p  0.02, †p  0.001, ‡p  0.03.5-mg-dose group), serum aminotransferase concentrations
c
8 times the upper limit of normal developed, but the
erum aminotransferase concentrations returned to the nor-
al range within 6 weeks of drug discontinuation. In a
econd patient (5-mg-dose group), isolated aspartate ami-
otransferase concentrations 3 times the upper limit of
ormal developed that resulted in dose reduction and
ventual discontinuation of drug during a separate long-
erm study (week 28). This patient was also receiving
oncomitant human immunodeficiency virus therapy. Two
atients in the 2.5-mg-dose group had isolated elevations
3 times the upper limit of normal that were unconfirmed
n re-testing and required no change in treatment. By the
nd of the open-label extension period (week 24), 48% of
he patients were receiving a dose of 10 mg; in none of these
atients did serum aminotransferase concentrations 3
imes the upper limit of normal develop.
A mean reduction of 0.8 g/dl of hemoglobin concentra-
ion was observed at week 12 in all dose groups combined,
ut no further decreases were observed in the open-label
xtension period. No clinically relevant changes were ob-
erved for prothrombin time, international normalized ratio,
r dose of anticoagulation therapy.
ISCUSSION
his trial has shown that ambrisentan, an ETA-selective
eceptor antagonist, seems to improve exercise capacity,
ymptoms, and hemodynamics in patients with PAH. The
bserved improvements in exercise capacity and hemody-
amics seem to be comparable with those achieved by other
igure 3. Mean change from baseline in 6-min walk distance (6MWD) for
ll dose group combined (n  64) up to 24 weeks. Error bars indicate
tandard error of the mean. *p  0.001.
igure 4. Change from baseline in World Health Organization functional
lass for all dose groups combined of ambrisentan up to 24 weeks. Higher
lasses indicate a greater severity of disease. Black bars class I; ruled bars
class II; open bars  class III.
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Ambrisentan and PAH August 2, 2005:529–35RAs in similar patient populations (13), even if the lack of
omparison with a placebo-treated group represents a lim-
tation of this study (10,14). However, in the majority of
andomized controlled trials performed in PAH, a deterio-
ation of some extent has been invariably observed in both
xercise capacity and hemodynamics in placebo-treated
atients (15), resulting in an amplification of the treatment
ffect. The sustained efficacy on exercise capacity observed at
eek 24 suggests that the results seen in this trial were not
aused by a placebo effect; however, we cannot exclude a
lacebo effect on more subjective parameters such as WHO
lass and subject global assessment.
No dose-response for efficacy as assessed by the 6MWD,
HO functional class, time to clinical worsening, or
emodynamics was observed in this study. A possible
xplanation for the lack of a clear dose-response may include
significant ET-receptor occupancy for a wide range of
oses and plasma drug concentrations. Alternatively, the
ack of a dose-response may be attributable to the small
ample size of the population studied. Of note, little
ose-response has been observed in other ERA studies in
AH—the BREATHE-1 study (10) showed a non-
tatistically significant trend toward a larger increase in
MWD with the higher dose of bosentan, whereas no
ose-response was observed for 6MWD in the sitaxsentan
TRIDE-1 study (14). Furthermore, no differences were
bserved in the STRIDE-1 study for the hemodynamic
ffects of two doses of sitaxsentan. In contrast, data from the
- and 10-mg ambrisentan dose groups suggest a better
emodynamic effect compared with the two lower doses;
owever, the number of patients evaluated was small and
he difference may be attributable to chance.
The dose escalation scheme in the randomized part of
his study resulted in a longer duration of exposure before
he assessment of the efficacy end points for the 1- and
.5-mg doses (12 weeks) as compared with the 5-mg (10
eeks) and 10-mg (8 weeks) doses. It is possible that these
isparities may have prevented the detection of meaningful
ifferences among dose groups.
The improvement in 6MWD observed at 12 weeks
36.1 m) tended to increase further up to 24 weeks when
ose adjustments were allowed, reaching a mean increase of
54.2 m. The larger response observed at week 24 in
atients with IPAH as compared with the other PAH
tiologies (mainly scleroderma) has been reported with the
ual ERA bosentan (10,14); however, it is worth noting
hat the improvement observed in patients with associated
AH in this study was not caused by a placebo deteriora-
able 3. Incidence and Severity of Aminotransferase Abnormaliti
Ambrisentan Dose
1 mg
(n  16)
3 and 5 times the upper limit of normal, n (%) 0 (0)
5 and 8 times the upper limit of normal, n (%) 0 (0)
8 times the upper limit of normal, n (%) 0 (0)ion, as was reported in the BREATHE-1 study (10). It is wlso interesting to note that WHO functional class II
atients respond similarly to treatment with ambrisentan as
HO functional class III patients (37.7 m and 35.2,
espectively) despite a statistically significant difference in
MWD between these two groups at baseline (390 m and
16 m, respectively; p  0.0002). This lack of a “ceiling
ffect” is in contrast to what was reported in a previous trial
ith another ETA-selective receptor antagonist (14).
The additional improvement of exercise capacity beyond
he first 12 weeks of treatment is difficult to explain by the
igher doses received in the open-label extension period
ecause of the lack of a dose-response relationship in the
receding period. One possibility is that the number of
atients per dose group during the first 12 weeks was too
mall to observe a clear dose-response, whereas during the
econd 12 weeks nearly three-quarters of all patients were
eceiving the two highest doses. In addition, a total of 56
atients continued treatment in the optional open-label
xtension period, which may constitute a selection of the
est responders to the treatment. However, an increase in
xercise capacity beyond the first months of therapy has also
een reported with the dual ERA bosentan (16) and may
epresent a characteristic of this class of drugs that is
ssociated with inhibition of smooth muscle cell prolifera-
ion and vascular remodeling.
An explanation for the tendency to increase the dose of
mbrisentan during the open-label part of the study is not
lear. One possible reason could be the attempt of physi-
ians to further improve the exercise capacity of those
atients who were tolerating ambrisentan with minimal
dverse events.
Elevations in serum aminotransferase concentrations 3
imes the upper limit of normal were observed in two
atients (3.1%) receiving the 5-mg dose. No patient devel-
ped serum aminotransferase concentrations 3 times the
pper limit of normal at the highest dose tested (10 mg),
ven when nearly half of the patients received the 10-mg
ose during the open-label extension period. Furthermore,
n only one patient (1.6%) in this 24-week study did
minotransferase concentrations 8 times the upper limit
f normal that required discontinuation of study drug
evelop. This low overall incidence and severity of serum
minotransferase abnormalities was not dose-dependent, in
ontrast to previous studies with bosentan (12% and 14%
fter 125- and 250-mg b.i.d. dose, respectively) (10) and
itaxsentan (5% and 21% after 100- and 300-mg once-daily
ose, respectively) (14).
Clinical worsening of PAH and mortality in this study
2.5 mg
(n  19)
5 mg
(n  16)
10 mg
(n  13)
All Doses
(n  64)
0 (0) 1 (6.2) 0 (0) 1 (1.6)
0 (0) 0 (0) 0 (0) 0 (0)
0 (0) 1 (6.2) 0 (0) 1 (1.6)esere similar to those observed in other randomized clinical
t
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August 2, 2005:529–35 Ambrisentan and PAHrials in this patient population (15). Interestingly, the great
ajority of worsening PAH in this study was characterized
y increases of diuretic dose (as defined in the study
rotocol). This phenomenon may be related to the occur-
ence of fluid retention and peripheral edema—a common
dverse effect of ERAs (14), and not necessarily associated
ith worsening of PAH. Also, although the incidence of
ther clinical adverse events was as expected with this class of
rug (10), it is important to note that no drug interactions with
arfarin-type anticoagulant treatment were observed (14).
In summary, ambrisentan, an ETA-selective receptor antag-
nist, seems to improve exercise capacity, symptoms, and
emodynamics in patients with WHO class II to III PAH.
mbrisentan may have a very favorable efficacy-to-safety ratio
n patients with PAH, including a low incidence and severity of
erum aminotransferase abnormalities that does not seem to be
ose-dependent. Phase III placebo-controlled trials are cur-
ently ongoing to confirm these initial results.
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PPENDIX
or a list of the additional members of the Ambrisentan
AH Study Group, please see the online version of this
rticle.
